RxDoctor Payments Data

Tiffany Polo

Nurse Practitioner · King William, VANPI 1548640873

Payments from drug & device makers

$2,219in general payments, 2019–2025

Across 103 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$318
  • Pfizer$228
  • AstraZeneca$220
  • Lilly USA, LLC$200
  • Novo Nordisk$191
  • Takeda Pharmaceuticals U.S.A., Inc.$158
  • plus $905 from 20 others

What the payments were for

  • Food & beverage$2,20199%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,219 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$38,108
Medicare patients
152
Services billed
493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$26,126
JardianceEmpagliflozin16$23,110
JanuviaSitagliptin Phosphate14$20,978
TrulicityDulaglutide12$20,403
XareltoRivaroxaban19$16,998
EliquisApixaban20$16,408
FarxigaDapagliflozin Propanediol11$13,439
DuleraMometasone/Formoterol11$4,296
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,028
Pravastatin Sodium127$1,451
Rosuvastatin Calcium92$1,374
Atorvastatin Calcium116$1,223
Amlodipine Besylate174$1,214
Levothyroxine Sodium91$928
Pantoprazole Sodium65$839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$191$26,12630 claims
Boehringer IngelheimJardiance$53$23,11016 claims
Lilly USA, LLCTrulicity$200$20,40312 claims
PfizerEliquis$228$16,40820 claims
AstraZenecaFarxiga$220$13,43911 claims
AbbVieSynthroid$318$70816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in King William

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →